Dr Bazhenova on the Need for Comprehensive Molecular Testing in Unresectable NSCLC

Lyudmila A. Bazhenova, MD, medical oncologist, professor, medicine, the University of California San Diego (UCSD) Moores Cancer Center, discusses key factors in the management of unresectable non–small cell lung cancer (NSCLC), emphasizing the importance of understanding and performing biomarker testing in this population.

Distinguishing between resectable and unresectable lung cancer is vital for selecting the most appropriate management approach, Bazhenova begins, adding that multidisciplinary collaboration allows for more informed decision-making. Although the current standard of care for patients with unresectable, stage III NSCLC is durvalumab (Imfinzi), this agent may not be advisable for use in patients expressing key oncogenic drivers, such as EGFR and ALK mutations, Bazhenova details.

Accordingly, comprehensive molecular testing is paramount for identifying which patients will benefit from available regimens, Bazhenova continues. Integrating DNA and RNA assessments into a routine molecular testing battery can be feasible and useful; however, it is important to understand the functional differences between DNA- and RNA-based tests to determine if 1 or both tests should be utilized. For example, information obtained from RNA-based testing can provide additional value for patients with gene fusions, Bazhenova says, noting that these can be prevalent in lung cancer. Understanding these nuances ensures more tailored and effective treatment strategies, Bazhenova emphasizes.

Lastly, it is critical to understand the challenges and limitations associated with the use of

cell-free DNA (cfDNA) as a diagnostic tool, Bazhenova states. Although cfDNA can be an effective, noninvasive diagnostic assay for patients with lung cancer, approximately 30% of cfDNA tests yield false negatives, she says. If liquid biopsy fails to identify a mutation, it is imperative not to halt the diagnostic journey, Bazhenova states. Performing additional tissue next-generation sequencing can potentially prevent clinicians from overlooking patients with underlying oncogenic drivers, she explains. This comprehensive approach ensures that patients receive the most accurate and beneficial diagnostic information, guiding personalized treatment plans for optimal outcomes, Bazhenova concludes.

spot_img

More from this stream

Recomended

Navigating a Second Trump Term: Keir Starmer’s Roadmap for the Future of the Special Relationship

Discover how Starmer is forging a positive working relationship with Trump and whether it's sufficient for future collaboration. Insights from The Converser.

Seven Key Questions About Trump’s Second Term – Insights from a Political Expert

Discover expert insights on Donald Trump's expected priorities and what his supporters hope to see achieved during his tenure. Read this in-depth analysis from The Converser.

“From Grit to Grace: Inspiring Journeys of Former Gangsters Reclaiming Their Lives”

Explore insights from gang expert Dennis Rodgers and Gaz, a former gang leader from Sierra Leone, in an engaging interview featured on The Converser. Tune in to The Conversation Weekly for an in-depth discussion on gang culture and its complexities.

Discover the Heartwarming Adventures of Paddington in Peru: A Tale of Kindness, Community, and Family Fun!

Join Paddington on a heartwarming journey back to Peru as he discovers the true meaning of home in his latest adventure. Source: The Converser.

“Trump’s Health Pick: A Recipe for Global Health Crisis and Twisted Realities”

Discover a concerning future where truth and science are overshadowed. Explore insights and implications on this pressing issue, brought to you by The Converser.

The Fall of Germany’s Government: Insights and Future Implications

Chancellor Olaf Scholz is poised to call for fresh elections in the new year following the dismissal of his coalition partner, as reported by The Converser. Stay updated on this pivotal political development.